(SSO); EGFR family; breast cancer Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo T O Nielsen1, S Sorensen2, F Dagnæs-Hansen3, J Kjems2 and B S Sorensen*,1 1Department of Clinical ...
Taken together, our data suggest that HER4 expression is suppressed in breast tumor cells through hypermethylation of multiple CpG sites within the HER4 promoter. 5215 Results and discussion The HER4 promoter is hypermethylated in HER4-negative breast tumor cell lines In breast cancer, aberrant ...
The DFS of postmenopausal and TAM-treated women tends to be significantly better in case of HER4-negative BC compared with HER4-positive BC (p = 0.0477; Fig. 1, bottom row). Fig. 1 Disease outcome of TAM-treated ER-positive breast cancer patients. OS and DFS are displayed for all ...
extracellular domain (ECD) and the transmembrane domain (TM) of Her-2/neu, but not the intracellular domain (ICD) of Her-2/neu, and GM-CSF to a mammal in need of treatment of a Her-2/neu-over-expressing human cancer, thereby treating said Her-2/neu-over-expressing human cancer. ...
10. Personal stress relief:Our pets react to our emotions, so if you’re stressed, your pet will too. Are you stressed out when you leave the house? Do act like you’re worried about your dog? If so, the pet will pick up on your feelings. When your animal is anxious, don’t mak...
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970. Sj?gren S, Ingan?s M, Lindgren A, et al. Prognostic and predictive value of...
Negative controls for the assays included an irrelevant HER500 peptide, no peptide, and each EBV-LcL line alone. Autologous EBV-LcLs were also run with each condition as a control for clone HER500.23c21 specificity. The assays were set up in 96 well round bottom plates in cRPMI+10% FBS ...
HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J. Mammary Gland Biol. Neoplasia 13, 247–258. https://doi.org/10.1007/s10911-008-9076-6 (2008). Article PubMed PubMed Central Google Scholar McGranahan, N. & Swanton, C. Clonal heterogeneity ...
HER4 activation by its ligand (NRG) leads to auto phosphorylation of its tyrosine residues, along with proteolytic cleavage and accumulation of an intracellular 80-kd fragment (4ICD) [32]. In breast cancer, HER4 knockdown has been suggested to induce apoptosis in cells that are resistant to ...